arecaidine has been researched along with Glioblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calogero, A; Castigli, E; Conte, C; Di Bari, M; Fabbiano, C; Ferretti, M; Ponti, D; Raco, A; Ricordy, R; Ruggieri, P; Sciaccaluga, M; Tata, AM | 1 |
| Calogero, A; Di Bari, M; Fabbiano, C; Ferretti, M; Ponti, D; Tata, AM | 1 |
2 other study(ies) available for arecaidine and Glioblastoma
| Article | Year |
|---|---|
M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arecoline; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Inhibitory Concentration 50; Muscarinic Agonists; Muscarinic Antagonists; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Muscarinic M2; Signal Transduction | 2013 |
M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines.
Topics: Arecoline; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Receptor, Muscarinic M2; Reverse Transcriptase Polymerase Chain Reaction | 2012 |